DA
DCF Advisers Portfolio holdings
AUM
$208M
This Quarter Return
+0.02%
1 Year Return
+21.52%
3 Year Return
+75.42%
5 Year Return
+129.34%
10 Year Return
–
AUM
$143M
AUM Growth
+$143M
(-1.1%)
Cap. Flow
+$631K
Cap. Flow
% of AUM
0.44%
Top 10 Holdings %
Top 10 Hldgs %
49.67%
Holding
84
New
4
Increased
22
Reduced
22
Closed
2
Top Buys
| 1 |
iShares Russell 2000 ETF
IWM
|
$1.45M |
| 2 |
Advanced Micro Devices
AMD
|
$1.05M |
| 3 |
SPDR S&P Biotech ETF
XBI
|
$986K |
| 4 |
Alpha Architect 1-3 Month Box ETF
BOXX
|
$778K |
| 5 |
Xencor
XNCR
|
$631K |
Top Sells
| 1 |
Amgen
AMGN
|
$2.28M |
| 2 |
argenx
ARGX
|
$1.82M |
| 3 |
Johnson & Johnson
JNJ
|
$718K |
| 4 |
Palo Alto Networks
PANW
|
$639K |
| 5 |
EOG Resources
EOG
|
$521K |
Sector Composition
| 1 | Healthcare | 42.6% |
| 2 | Technology | 19.34% |
| 3 | Communication Services | 8.69% |
| 4 | Consumer Discretionary | 4.34% |
| 5 | Financials | 3.81% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Evotec
EVO
$1.22B
| $484K | 0.26% |
49,047
+6,309
| +15% | +$62.3K |
|
52
iShares MSCI Emerging Markets ETF
EEM
$19B
| $474K | 0.26% |
12,500
| – | – |
|
53
Teva Pharmaceuticals
TEVA
$21.5B
| $454K | 0.25% |
44,500
+5,500
| +14% | +$56.1K |
|
54
Boeing
BA
$176B
| $383K | 0.21% |
2,000
-500
| -20% | -$95.8K |
|
55
Alnylam Pharmaceuticals
ALNY
$58.6B
| $319K | 0.17% |
1,800
+200
| +13% | +$35.4K |
|
56
Lam Research
LRCX
$124B
| $313K | 0.17% |
500
| – | – |
|
57
Altimmune
ALT
$325M
| $312K | 0.17% |
119,975
| – | – |
|
58
Spotify
SPOT
$143B
| $309K | 0.17% |
2,000
| – | – |
|
59
Bristol-Myers Squibb
BMY
$96.7B
| $305K | 0.17% |
+5,250
| New | +$305K |
|
|
RVNC
60
DELISTED
Revance Therapeutics, Inc.
RVNC
| $304K | 0.17% |
+26,500
| New | +$304K |
|
61
Citigroup
C
$175B
| $298K | 0.16% |
7,250
| – | – |
|
62
VanEck Gold Miners ETF
GDX
$19.6B
| $283K | 0.15% |
10,500
| – | – |
|
|
63
Johnson & Johnson
JNJ
$429B
| $234K | 0.13% |
1,500
-4,613
| -75% | -$718K |
|
64
Viridian Therapeutics
VRDN
$1.59B
| $207K | 0.11% |
13,500
-5,500
| -29% | -$84.4K |
|
65
Air T
AIRT
| $204K | 0.11% |
9,135
| – | – |
|
|
IMGN
66
DELISTED
Immunogen Inc
IMGN
| $204K | 0.11% |
12,850
+2,500
| +24% | +$39.7K |
|
|
PARA
67
DELISTED
Paramount Global Class B
PARA
| $161K | 0.09% |
12,500
| – | – |
|
68
Ovid Therapeutics
OVID
$94.6M
| $117K | 0.06% |
30,430
-34,334
| -53% | -$132K |
|
69
United States Natural Gas Fund
UNG
$621M
| $102K | 0.06% |
15,000
| – | – |
|
70
Lineage Cell Therapeutics
LCTX
$281M
| $97.6K | 0.05% |
82,751
+67,751
| +452% | +$79.9K |
|
71
Vir Biotechnology
VIR
$765M
| $93.7K | 0.05% |
10,000
-45,000
| -82% | -$422K |
|
|
IMPL
72
DELISTED
Impel Pharmaceuticals Inc. Common Stock
IMPL
| $76.8K | 0.04% |
178,500
-125,105
| -41% | -$53.8K |
|
|
TBHC
73
The Brand House Collective, Inc. Common Stock
TBHC
$33.5M
| $60.6K | 0.03% |
35,235
+8,000
| +29% | +$13.8K |
|
74
Equillium
EQ
$66.8M
| $51.7K | 0.03% |
69,871
-41,752
| -37% | -$30.9K |
|
|
AMRN
75
Amarin Corp
AMRN
$311M
| $13K | 0.01% |
14,100
-10,900
| -44% | -$10K |
|